Sign In
Buy TARS
$59.04
-0.500 (-0.84%)
At Close: Jul 31, 2026
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
11:02am, Wednesday, 29'th Jul 2026
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Caxton Associates LLP Has $1.06 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS
03:52am, Monday, 27'th Jul 2026
Caxton Associates LLP cut its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 63.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
11:57am, Friday, 24'th Jul 2026
TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. TARS reiterates 2026 Xdemvy net sales guidance of $670M–$700M, with Q2'26 prescript
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
04:05pm, Monday, 13'th Jul 2026
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new op
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
10:02am, Saturday, 11'th Jul 2026
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company s
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
01:01pm, Thursday, 09'th Jul 2026
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
02:12am, Thursday, 09'th Jul 2026
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
04:05pm, Wednesday, 08'th Jul 2026
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
01:01pm, Wednesday, 08'th Jul 2026
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
06:06am, Friday, 03'rd Jul 2026
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Tarsus to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 28'th May 2026
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
10:43am, Friday, 15'th May 2026
Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but of
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
09:20pm, Tuesday, 12'th May 2026
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 07'th May 2026
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
